查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
脊髓性肌萎縮症 (SMA) 治療全球市場規模和預測：按產品、按疾病類型、按分銷渠道、按地區，2022-2029 年
市場調查報告書
商品編碼
1215324

脊髓性肌萎縮症 (SMA) 治療全球市場規模和預測：按產品、按疾病類型、按分銷渠道、按地區，2022-2029 年

Global Spinal Muscular Atrophy Treatment Market Size study & Forecast, by Product, by Disease Type, by Distribution Channel and Regional Analysis, 2022-2029
出版日期: | 出版商: Bizwit Research & Consulting LLP | 英文 | 商品交期: 2-3個工作天內

價格

2021 年全球脊髓性肌萎縮症治療市場價值約 38.8 億美元，在 2022-2029 年預測期內以超過 18.6% 的健康增長率增長 據預測

脊髓性肌萎縮症 (SMA) 是一種遺傳性疾病，會逐漸破壞脊髓和腦幹中的運動神經元。 它還影響重要的骨骼肌活動，如呼吸、行走、說話和吞嚥，導致肌肉無力和萎縮。 對新療法的認識提高、政府支持增加以及醫療保健成本上升是推動全球市場增長的主要因素。

脊髓性肌萎縮症患病率呈上升趨勢，這與全球市場需求直接相關。 根據國家罕見病組織 (NORD) 的估計，全世界大約每 10,000 人中就有 1 人患有脊髓性肌萎縮症 (SMA)。 同樣，據脊髓性肌萎縮症基金會稱，預計該疾病將影響全球 6,000 至 10,000 名新生兒中的 1 名。 因此，這種疾病發病率的增加對市場需求做出了積極貢獻，從而推動了市場增長。 此外，新的高效產品的推出和研發投資的增加在預測期內創造了各種機會。 然而，與獲批產品相關的高成本和熟練專業人員的短缺限制了整個 2022-2029 年預測期內的市場增長。

全球脊髓性肌萎縮症治療市場研究考慮的主要區域包括亞太地區、北美、歐洲、拉丁美洲和世界其他地區。 由於治療產品支出的增加和人口中 SMA 疾病發病率的上升，北美在收入方面佔據了市場主導地位。 另一方面，由於目標人口的增長、醫療保健服務支出的增加以及市場空間主要參與者的地域擴張等因素，預計亞太地區在預測期內將以最高的複合年增長率增長。

本報告中包含的主要市場參與者是：

  • 百健
  • 諾華公司
  • Ionis Pharmaceuticals, Inc.
  • Biohaven 製藥公司
  • F. Hoffmann-La Roche
  • 細胞動力學
  • 標量巖
  • PTC 治療
  • NMD 製藥公司
  • 安斯泰來製藥公司
市場的

近期發展。

  • 2022 年 1 月，百健（Biogen）和 Ionis Pharmaceuticals 簽訂了開發另一種實驗藥物 BIIB115 的許可協議，BIIB115 是一種反義寡核甘酸，旨在治愈 SMA 患者。 BIIB115是臨床前試驗中的實驗藥物。 該協議的目的是擴大百健（Biogen）公司的 SMA 治療產品組合。
  • 2019 年 5 月，諾華公司宣布 Zolgensma (onasemnogene abeparvovec-xioi) 獲得美國 FDA 批准，成為首個也是唯一一個用於小兒脊髓性肌萎縮症 (SMA) 患者的基因療法。底部。

全球脊髓性肌萎縮症藥物市場研究範圍。

  • 歷史數據：2019-2020-2021
  • 基本估算年份：2021 年
  • 預測期間：2022-2029
  • 報告範圍利潤預測、公司排名、競爭格局、增長因素和趨勢
  • 涵蓋的細分市場產品類型、疾病類型、分銷渠道、地區
  • 區域覆蓋範圍 北美；歐洲；亞太地區；拉丁美洲；世界其他地區
  • 自定義範圍 報告自定義是免費的（最多 8 小時的分析師工作）。 添加或更改國家、地區或細分範圍*。

這項研究的目的是定義近年來各個細分市場和國家的市場規模，並預測他們在未來幾年的價值。 該報告旨在捕捉被調查國家工業的定性和定量方面。

它還提供了關鍵方面的詳細信息，例如決定市場未來增長的驅動因素和挑戰。 此外，它還包含供利益相關者投資的微觀市場潛在機會，以及對主要參與者的競爭格局和產品供應的深入分析。

按產品

  • 努西內森
  • Onasemnogen Abeparvovec

按疾病類型

  • 1 型 SMA
  • 2 型 SMA
  • 其他

按銷售渠道

  • 醫院藥房
  • 零售店
  • 其他

按地區

  • 北美
  • 美國
  • 加拿大
  • 歐洲
  • 英國
  • 德國
  • 法國
  • 西班牙
  • 意大利
  • 淨資產收益率
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳大利亞
  • 韓國
  • 下包
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 羅拉
  • 世界其他地方

內容

第 1 章執行摘要

  • 市場概況
  • 2019-2029 年各細分市場的全球市場估計和預測
    • 脊髓性肌萎縮症治療市場：按地區劃分，2019-2029 年
    • 脊髓性肌萎縮症市場：按產品分類，2019-2029 年
    • 脊髓性肌萎縮症治療市場：按疾病類型分類，2019-2029 年
    • 脊髓性肌萎縮症市場：分銷渠道，2019-2029 年
  • 主要趨勢
  • 調查方法
  • 調查先決條件

第 2 章脊髓性肌萎縮症藥物的全球市場定義和範圍

  • 調查的目的
  • 市場定義和範圍
    • 調查範圍
    • 工業發展
  • 調查年份
  • 貨幣兌換率

第 3 章全球脊髓性肌萎縮症治療市場動態

  • 脊髓性肌萎縮症藥物市場影響分析（2019-2029）
    • 市場驅動因素
      • 提高對新療法的認識
      • 脊髓性肌萎縮症患病率上升
    • 市場挑戰
      • 與獲批產品相關的高成本
      • 缺乏熟練的專業人員
    • 市場機會
      • 推出具有高效能的新產品
      • 擴大研發投資

第 4 章全球脊髓性肌萎縮症治療市場行業分析

  • 波特 5 力模型
    • 供應商的議價能力
    • 買家的議價能力
    • 新進入者的威脅
    • 替代品的威脅
    • 競爭公司之間的敵對關係
  • 波特 5 力模型的未來方法 (2019-2029)
  • 害蟲分析
    • 政治
    • 經濟的
    • 社交
    • 技術
  • 頂級投資機會
  • 關鍵成功策略
  • 行業專家的展望
  • 分析師的結論和建議

第 5 章風險評估：COVID-19 的影響

  • 評估 COVID-19 對行業的總體影響
  • COVID-19 之前和 COVID-19 之後的市場情景

第 6 章全球脊髓性肌萎縮症治療市場：副產品

  • 市場概況
  • 全球脊髓性肌萎縮症治療市場：按產品分類的性能潛力分析
  • 2019-2029 年按產品分列的脊髓性肌萎縮症治療全球市場估計和預測
  • 脊髓性肌萎縮症治療市場，細分分析
    • 努西內森
    • Onasemnogen Abeparvovec

第 7 章：脊髓性肌萎縮症治療藥物的全球市場，按疾病類型分類

  • 市場概況
  • 全球脊髓性肌萎縮症治療市場：按疾病類型進行性能潛力分析
  • 2019-2029 年全球脊髓性肌萎縮症治療市場、按疾病類型估計和預測
  • 脊髓性肌萎縮症治療市場，細分分析
    • 1 型 SMA
    • 2 型 SMA
    • 其他

第 8 章脊髓性肌萎縮症藥物的全球市場：按分銷渠道

  • 市場概況
  • 全球脊髓性肌萎縮症藥物市場：按分銷渠道進行的性能潛力分析
  • 2019-2029 年全球脊髓性肌萎縮症治療藥物市場、分銷渠道估計和預測
  • 脊髓性肌萎縮症治療市場，細分分析
    • 醫院藥房
    • 零售藥房
    • 其他

第 9 章脊髓性肌萎縮症藥物的全球市場：區域分析

  • 脊髓性肌萎縮症藥物市場，按地區劃分的市場概況
  • 北美
    • 美國
      • 2019-2029 年按產品估算和預測
      • 按疾病類型估算和預測，2019-2029 年
      • 2019-2029 年各分銷渠道的估計和預測
    • 加拿大
  • 歐洲脊髓性肌萎縮症藥物市場概況
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 意大利
    • 其他歐洲地區
  • 亞太地區脊髓性肌萎縮症治療市場概況
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 韓國
    • 其他亞太地區
  • 拉丁美洲脊髓性肌萎縮症治療市場概況
    • 巴西
    • 墨西哥
    • 其他拉丁美洲地區
  • 世界其他地方

第 10 章衝突信息

  • 頂級市場策略
  • 公司簡介
    • 百健
      • 主要信息
      • 概覽
      • 財務信息（取決於數據可用性）
      • 產品概述
      • 近期趨勢
    • Novartis AG
    • Ionis Pharmaceuticals Inc.
    • Biohaven Pharmaceuticals
    • F. Hoffmann-La Roche Ltd
    • Cytokinetics
    • Scholar Rock, Inc.
    • PTC Therapeutics
    • NMD PHARMA A/S
    • Astellas Pharma Inc.

第 11 章研究過程

  • 研究過程
    • 數據挖掘
    • 分析
    • 市場評估
    • 驗證
    • 出版
  • 調查屬性
  • 調查先決條件

Global Spinal Muscular Atrophy Treatment Market is valued at approximately USD 3.88 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 18.6% over the forecast period 2022-2029. Spinal muscular atrophy (SMA) is a type of genetic disease that gradually destroys motor neurons that are the spinal cord and nerve cells in the brain stem. It also affects vital skeletal muscle activity including breathing, walking, speaking, and swallowing, which leads to muscle weakness and atrophy. The growing awareness regarding novel therapies, rising government support, coupled with increasing healthcare expenditure is primary factors that are fostering market growth across the globe.

The prevalence of spinal muscular atrophy is on the rise which is directly associated with the market demand across the globe. The National Organization for Rare Disorders (NORD) estimates that approximately 1 in 10,000 people worldwide suffer with spinal muscular atrophy (SMA). Likewise, according to the Spinal Muscular Atrophy Foundation, the condition is expected to affect 1 in every 6,000 to 10,000 newborns worldwide. Therefore, the growing incidences of the disorder are actively contributing to market demand, which, in turn, fosters the growth of the market. Moreover, the introduction of new product with high efficacies, as well as growing R&D investments are presenting various lucrative opportunities over the forecasting years. However, the high costs associated with the approved products and the dearth of skilled professionals are restricting the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Spinal Muscular Atrophy Treatment Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the market in terms of revenue, owing to the growing spending on treatment products and the rising incidence of SMA disorders among the population. Whereas, the Asia Pacific is also expected to grow with the highest CAGR during the forecast period, owing to factors such as rising target populations, increasing expenditure on healthcare services, and geographic expansion of key players in the market space.

Major market players included in this report are:

  • Biogen
  • Novartis AG
  • Ionis Pharmaceuticals Inc.
  • Biohaven Pharmaceuticals
  • F. Hoffmann-La Roche Ltd
  • Cytokinetics
  • Scholar Rock, Inc.
  • PTC Therapeutics
  • NMD PHARMA A/S
  • Astellas Pharma Inc.

Recent Developments in the Market:

  • In January 2022, Biogen and Ionis Pharmaceuticals, Inc., declare that the companies entered into licensing agreement with the aim of developing another experimental drug BIIB115 (an antisense oligonucleotide) to cure of patients with SMA. BIIB115 is an experimental preclinical-stage drug. The objective of this agreement is to expand Biogen's SMA drug portfolio.
  • In May 2019, Novartis AG announced that its Zolgensma (onasemnogene abeparvovec-xioi) received an approval from the U.S. FDA for the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA).

Global Spinal Muscular Atrophy Treatment Market Report Scope:

  • Historical Data: 2019-2020-2021
  • Base Year for Estimation: 2021
  • Forecast period: 2022-2029
  • Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: Product, Disease Type, Distribution Channel, Region
  • Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World
  • Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:

  • Nusinersen
  • Onasemnogen Abeparvovec

By Disease Type:

  • Type 1 SMA
  • Type 2 SMA
  • Others

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • RoLA
  • Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
    • 1.2.1. Spinal Muscular Atrophy Treatment Market, by Region, 2019-2029 (USD Billion)
    • 1.2.2. Spinal Muscular Atrophy Treatment Market, by Product, 2019-2029 (USD Billion)
    • 1.2.3. Spinal Muscular Atrophy Treatment Market, by Disease Type, 2019-2029 (USD Billion)
    • 1.2.4. Spinal Muscular Atrophy Treatment Market, by Distribution Channel, 2019-2029 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Spinal Muscular Atrophy Treatment Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Spinal Muscular Atrophy Treatment Market Dynamics

  • 3.1. Spinal Muscular Atrophy Treatment Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing awareness regarding novel therapies
      • 3.1.1.2. Growing prevalence of spinal muscular atrophy
    • 3.1.2. Market Challenges
      • 3.1.2.1. High costs associated with the approved products
      • 3.1.2.2. Dearth of skilled professionals
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Introduction of new product with high efficacies
      • 3.1.3.2. Growing R&D investments

Chapter 4. Global Spinal Muscular Atrophy Treatment Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. Industry Experts Prospective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Spinal Muscular Atrophy Treatment Market, by Product

  • 6.1. Market Snapshot
  • 6.2. Global Spinal Muscular Atrophy Treatment Market by Product, Performance - Potential Analysis
  • 6.3. Global Spinal Muscular Atrophy Treatment Market Estimates & Forecasts by Product 2019-2029 (USD Billion)
  • 6.4. Spinal Muscular Atrophy Treatment Market, Sub Segment Analysis
    • 6.4.1. Nusinersen
    • 6.4.2. Onasemnogen Abeparvovec

Chapter 7. Global Spinal Muscular Atrophy Treatment Market, by Disease Type

  • 7.1. Market Snapshot
  • 7.2. Global Spinal Muscular Atrophy Treatment Market by Disease Type, Performance - Potential Analysis
  • 7.3. Global Spinal Muscular Atrophy Treatment Market Estimates & Forecasts by Disease Type 2019-2029 (USD Billion)
  • 7.4. Spinal Muscular Atrophy Treatment Market, Sub Segment Analysis
    • 7.4.1. Type 1 SMA
    • 7.4.2. Type 2 SMA
    • 7.4.3. Others

Chapter 8. Global Spinal Muscular Atrophy Treatment Market, by Distribution Channel

  • 8.1. Market Snapshot
  • 8.2. Global Spinal Muscular Atrophy Treatment Market by Distribution Channel, Performance - Potential Analysis
  • 8.3. Global Spinal Muscular Atrophy Treatment Market Estimates & Forecasts by Distribution Channel 2019-2029 (USD Billion)
  • 8.4. Spinal Muscular Atrophy Treatment Market, Sub Segment Analysis
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Retail Pharmacies
    • 8.4.3. Others

Chapter 9. Global Spinal Muscular Atrophy Treatment Market, Regional Analysis

  • 9.1. Spinal Muscular Atrophy Treatment Market, Regional Market Snapshot
  • 9.2. North America Spinal Muscular Atrophy Treatment Market
    • 9.2.1. U.S. Spinal Muscular Atrophy Treatment Market
      • 9.2.1.1. Product breakdown estimates & forecasts, 2019-2029
      • 9.2.1.2. Disease Type breakdown estimates & forecasts, 2019-2029
      • 9.2.1.3. Distribution Channel breakdown estimates & forecasts, 2019-2029
    • 9.2.2. Canada Spinal Muscular Atrophy Treatment Market
  • 9.3. Europe Spinal Muscular Atrophy Treatment Market Snapshot
    • 9.3.1. U.K. Spinal Muscular Atrophy Treatment Market
    • 9.3.2. Germany Spinal Muscular Atrophy Treatment Market
    • 9.3.3. France Spinal Muscular Atrophy Treatment Market
    • 9.3.4. Spain Spinal Muscular Atrophy Treatment Market
    • 9.3.5. Italy Spinal Muscular Atrophy Treatment Market
    • 9.3.6. Rest of Europe Spinal Muscular Atrophy Treatment Market
  • 9.4. Asia-Pacific Spinal Muscular Atrophy Treatment Market Snapshot
    • 9.4.1. China Spinal Muscular Atrophy Treatment Market
    • 9.4.2. India Spinal Muscular Atrophy Treatment Market
    • 9.4.3. Japan Spinal Muscular Atrophy Treatment Market
    • 9.4.4. Australia Spinal Muscular Atrophy Treatment Market
    • 9.4.5. South Korea Spinal Muscular Atrophy Treatment Market
    • 9.4.6. Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market
  • 9.5. Latin America Spinal Muscular Atrophy Treatment Market Snapshot
    • 9.5.1. Brazil Spinal Muscular Atrophy Treatment Market
    • 9.5.2. Mexico Spinal Muscular Atrophy Treatment Market
    • 9.5.3. Rest of Latin America Spinal Muscular Atrophy Treatment Market
  • 9.6. Rest of The World Spinal Muscular Atrophy Treatment Market

Chapter 10. Competitive Intelligence

  • 10.1. Top Market Strategies
  • 10.2. Company Profiles
    • 10.2.1. Biogen
      • 10.2.1.1. Key Information
      • 10.2.1.2. Overview
      • 10.2.1.3. Financial (Subject to Data Availability)
      • 10.2.1.4. Product Summary
      • 10.2.1.5. Recent Developments
    • 10.2.2. Novartis AG
    • 10.2.3. Ionis Pharmaceuticals Inc.
    • 10.2.4. Biohaven Pharmaceuticals
    • 10.2.5. F. Hoffmann-La Roche Ltd
    • 10.2.6. Cytokinetics
    • 10.2.7. Scholar Rock, Inc.
    • 10.2.8. PTC Therapeutics
    • 10.2.9. NMD PHARMA A/S
    • 10.2.10. Astellas Pharma Inc.

Chapter 11. Research Process

  • 11.1. Research Process
    • 11.1.1. Data Mining
    • 11.1.2. Analysis
    • 11.1.3. Market Estimation
    • 11.1.4. Validation
    • 11.1.5. Publishing
  • 11.2. Research Attributes
  • 11.3. Research Assumption

LIST OF TABLES

  • TABLE 1. Global Spinal Muscular Atrophy Treatment Market, report scope
  • TABLE 2. Global Spinal Muscular Atrophy Treatment Market estimates & forecasts by Region 2019-2029 (USD Billion)
  • TABLE 3. Global Spinal Muscular Atrophy Treatment Market estimates & forecasts by Product 2019-2029 (USD Billion)
  • TABLE 4. Global Spinal Muscular Atrophy Treatment Market estimates & forecasts by Disease Type 2019-2029 (USD Billion)
  • TABLE 5. Global Spinal Muscular Atrophy Treatment Market estimates & forecasts by Distribution Channel 2019-2029 (USD Billion)
  • TABLE 6. Global Spinal Muscular Atrophy Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 7. Global Spinal Muscular Atrophy Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 8. Global Spinal Muscular Atrophy Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 9. Global Spinal Muscular Atrophy Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 10. Global Spinal Muscular Atrophy Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 11. Global Spinal Muscular Atrophy Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 12. Global Spinal Muscular Atrophy Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 13. Global Spinal Muscular Atrophy Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 14. Global Spinal Muscular Atrophy Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 15. Global Spinal Muscular Atrophy Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 16. U.S. Spinal Muscular Atrophy Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 17. U.S. Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 18. U.S. Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 19. Canada Spinal Muscular Atrophy Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 20. Canada Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 21. Canada Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 22. UK Spinal Muscular Atrophy Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 23. UK Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 24. UK Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 25. Germany Spinal Muscular Atrophy Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 26. Germany Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 27. Germany Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 28. France Spinal Muscular Atrophy Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 29. France Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 30. France Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 31. Italy Spinal Muscular Atrophy Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 32. Italy Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 33. Italy Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 34. Spain Spinal Muscular Atrophy Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 35. Spain Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 36. Spain Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 37. RoE Spinal Muscular Atrophy Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 38. RoE Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 39. RoE Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 40. China Spinal Muscular Atrophy Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 41. China Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 42. China Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 43. India Spinal Muscular Atrophy Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 44. India Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 45. India Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 46. Japan Spinal Muscular Atrophy Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 47. Japan Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 48. Japan Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 49. South Korea Spinal Muscular Atrophy Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 50. South Korea Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 51. South Korea Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 52. Australia Spinal Muscular Atrophy Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 53. Australia Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 54. Australia Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 55. RoAPAC Spinal Muscular Atrophy Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 56. RoAPAC Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 57. RoAPAC Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 58. Brazil Spinal Muscular Atrophy Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 59. Brazil Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 60. Brazil Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 61. Mexico Spinal Muscular Atrophy Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 62. Mexico Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 63. Mexico Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 64. RoLA Spinal Muscular Atrophy Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 65. RoLA Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 66. RoLA Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 67. Row Spinal Muscular Atrophy Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 68. Row Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 69. Row Spinal Muscular Atrophy Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 70. List of secondary sources, used in the study of global Spinal Muscular Atrophy Treatment Market
  • TABLE 71. List of primary sources, used in the study of global Spinal Muscular Atrophy Treatment Market
  • TABLE 72. Years considered for the study
  • TABLE 73. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global Spinal Muscular Atrophy Treatment Market, research methodology
  • FIG 2. Global Spinal Muscular Atrophy Treatment Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Spinal Muscular Atrophy Treatment Market, key trends 2021
  • FIG 5. Global Spinal Muscular Atrophy Treatment Market, growth prospects 2022-2029
  • FIG 6. Global Spinal Muscular Atrophy Treatment Market, porters 5 force model
  • FIG 7. Global Spinal Muscular Atrophy Treatment Market, pest analysis
  • FIG 8. Global Spinal Muscular Atrophy Treatment Market, value chain analysis
  • FIG 9. Global Spinal Muscular Atrophy Treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 10. Global Spinal Muscular Atrophy Treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 11. Global Spinal Muscular Atrophy Treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 12. Global Spinal Muscular Atrophy Treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 13. Global Spinal Muscular Atrophy Treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 14. Global Spinal Muscular Atrophy Treatment Market, regional snapshot 2019 & 2029
  • FIG 15. North America Spinal Muscular Atrophy Treatment Market 2019 & 2029 (USD Billion)
  • FIG 16. Europe Spinal Muscular Atrophy Treatment Market 2019 & 2029 (USD Billion)
  • FIG 17. Asia pacific Spinal Muscular Atrophy Treatment Market 2019 & 2029 (USD Billion)
  • FIG 18. Latin America Spinal Muscular Atrophy Treatment Market 2019 & 2029 (USD Billion)
  • FIG 19. Global Spinal Muscular Atrophy Treatment Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable